Advertisement

Back from the Brink: Catastrophic Antiphospholipid Syndrome

Published:January 14, 2015DOI:https://doi.org/10.1016/j.amjmed.2015.01.002
      Cardiogenic shock was the first sign of a devastating disorder in a 27-year-old woman with multiple medical problems. She presented to an outside hospital after 2 days of nausea, epigastric pain, and worsening dyspnea on exertion. Her medical history included systemic lupus erythematosus, autoimmune hepatitis, immune thrombocytopenia, autoimmune hemolytic anemia, attention deficit hyperactivity disorder, anxiety, and migraines.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Werdan K.
        • Gielen S.
        • Ebelt H.
        • Hochman J.S.
        Mechanical circulatory support in cardiogenic shock.
        Eur Heart J. 2014; 35: 156-167
        • Borisenko O.
        • Wylie G.
        • Payne J.
        • et al.
        Thoratec CentriMag for temporary treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency: a systematic literature review and meta-analysis of observational studies.
        ASAIO J. 2014; 60: 487-497
        • Ma P.
        • Zhang Z.
        • Song T.
        • et al.
        Combining ECMO with IABP for the treatment of critically Ill adult heart failure patients.
        Heart Lung Circ. 2014; 23: 363-368
        • Asherson R.A.
        • Espinosa G.
        • Cervera R.
        • Font J.
        • Reverter J.C.
        Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment.
        J Clin Rheumatol. 2002; 8: 157-165
        • Nayer A.
        • Ortega L.M.
        Catastrophic antiphospholipid syndrome: a clinical review.
        J Nephropathol. 2014; 3: 9-17
        • Repéssé X.
        • Freund Y.
        • Mathian A.
        • Hervier B.
        • Amoura Z.
        • Luyt C.E.
        Successful extracorporeal membrane oxygenation for refractory cardiogenic shock due to the catastrophic antiphospholipid syndrome.
        Ann Intern Med. 2010; 153: 487-488
        • Bucciarelli S.
        • Espinosa G.
        • Cervera R.
        • et al.
        Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients.
        Arthritis Rheum. 2006; 54: 2568-2576
        • Klein H.U.
        • Goldenberg I.
        • Moss A.J.
        Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
        Eur Heart J. 2013; 34: 2230-2242